Jorrit van Poelgeest, Shahriyar Shahbazi Khamas, Ahmed Hallawa, Cristian D'Alessandro, Ricardo Ferreira, Anke H Maitland-van der Zee, Paul Brinkman
{"title":"呼出的挥发性有机化合物与慢性阻塞性肺疾病加重相关——系统评价和验证","authors":"Jorrit van Poelgeest, Shahriyar Shahbazi Khamas, Ahmed Hallawa, Cristian D'Alessandro, Ricardo Ferreira, Anke H Maitland-van der Zee, Paul Brinkman","doi":"10.1088/1752-7163/adba06","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) exacerbations significantly contribute to disease progression, hospitalizations, and decreased quality of life. Early detection of exacerbations through non-invasive methods, such as exhaled volatile organic compounds (VOCs), could enable timely interventions. This study aimed to identify and validate candidate VOC biomarkers that are associated with exacerbations and stable phases of COPD, and could contribute to the development of a breath-based monitoring device. A systematic review was conducted to identify VOCs associated with COPD and exacerbations. VOCs were selected as candidate biomarkers if they were reported in at least two studies by different research groups. These VOCs were then validated using longitudinal exhaled breath data from the TEXACOLD study, where exhaled breath samples were collected at baseline, during exacerbation, and at follow-up in 14 COPD patients. Sparse partial least squares-discriminant analysis was applied to differentiate between samples collected during exacerbation and those at stable phases. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curves. The systematic review identified nine candidate VOCs. Three were excluded from validation because their dataset overlapped with one used in one of the included review studies. Validation confirmed the discriminatory power of a composite model of these six VOCs, achieving an area under the ROC curve of 0.98, a diagnostic accuracy of 94.3% and a sensitivity of 0.97 and a specificity of 0.93. This study demonstrates that exhaled VOCs can differentiate between exacerbations and stable phases in COPD patients. The validated biomarkers hold promise for future clinical applications, particularly in the development of a non-invasive, breath-based monitoring device for early detection and management of COPD exacerbations, potentially reducing hospitalizations and improving patient outcomes.</p>","PeriodicalId":15306,"journal":{"name":"Journal of breath research","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exhaled volatile organic compounds associated with chronic obstructive pulmonary disease exacerbations-a systematic review and validation.\",\"authors\":\"Jorrit van Poelgeest, Shahriyar Shahbazi Khamas, Ahmed Hallawa, Cristian D'Alessandro, Ricardo Ferreira, Anke H Maitland-van der Zee, Paul Brinkman\",\"doi\":\"10.1088/1752-7163/adba06\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chronic obstructive pulmonary disease (COPD) exacerbations significantly contribute to disease progression, hospitalizations, and decreased quality of life. Early detection of exacerbations through non-invasive methods, such as exhaled volatile organic compounds (VOCs), could enable timely interventions. This study aimed to identify and validate candidate VOC biomarkers that are associated with exacerbations and stable phases of COPD, and could contribute to the development of a breath-based monitoring device. A systematic review was conducted to identify VOCs associated with COPD and exacerbations. VOCs were selected as candidate biomarkers if they were reported in at least two studies by different research groups. These VOCs were then validated using longitudinal exhaled breath data from the TEXACOLD study, where exhaled breath samples were collected at baseline, during exacerbation, and at follow-up in 14 COPD patients. Sparse partial least squares-discriminant analysis was applied to differentiate between samples collected during exacerbation and those at stable phases. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curves. The systematic review identified nine candidate VOCs. Three were excluded from validation because their dataset overlapped with one used in one of the included review studies. Validation confirmed the discriminatory power of a composite model of these six VOCs, achieving an area under the ROC curve of 0.98, a diagnostic accuracy of 94.3% and a sensitivity of 0.97 and a specificity of 0.93. This study demonstrates that exhaled VOCs can differentiate between exacerbations and stable phases in COPD patients. The validated biomarkers hold promise for future clinical applications, particularly in the development of a non-invasive, breath-based monitoring device for early detection and management of COPD exacerbations, potentially reducing hospitalizations and improving patient outcomes.</p>\",\"PeriodicalId\":15306,\"journal\":{\"name\":\"Journal of breath research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-03-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of breath research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1088/1752-7163/adba06\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of breath research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1088/1752-7163/adba06","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
Exhaled volatile organic compounds associated with chronic obstructive pulmonary disease exacerbations-a systematic review and validation.
Chronic obstructive pulmonary disease (COPD) exacerbations significantly contribute to disease progression, hospitalizations, and decreased quality of life. Early detection of exacerbations through non-invasive methods, such as exhaled volatile organic compounds (VOCs), could enable timely interventions. This study aimed to identify and validate candidate VOC biomarkers that are associated with exacerbations and stable phases of COPD, and could contribute to the development of a breath-based monitoring device. A systematic review was conducted to identify VOCs associated with COPD and exacerbations. VOCs were selected as candidate biomarkers if they were reported in at least two studies by different research groups. These VOCs were then validated using longitudinal exhaled breath data from the TEXACOLD study, where exhaled breath samples were collected at baseline, during exacerbation, and at follow-up in 14 COPD patients. Sparse partial least squares-discriminant analysis was applied to differentiate between samples collected during exacerbation and those at stable phases. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curves. The systematic review identified nine candidate VOCs. Three were excluded from validation because their dataset overlapped with one used in one of the included review studies. Validation confirmed the discriminatory power of a composite model of these six VOCs, achieving an area under the ROC curve of 0.98, a diagnostic accuracy of 94.3% and a sensitivity of 0.97 and a specificity of 0.93. This study demonstrates that exhaled VOCs can differentiate between exacerbations and stable phases in COPD patients. The validated biomarkers hold promise for future clinical applications, particularly in the development of a non-invasive, breath-based monitoring device for early detection and management of COPD exacerbations, potentially reducing hospitalizations and improving patient outcomes.
期刊介绍:
Journal of Breath Research is dedicated to all aspects of scientific breath research. The traditional focus is on analysis of volatile compounds and aerosols in exhaled breath for the investigation of exogenous exposures, metabolism, toxicology, health status and the diagnosis of disease and breath odours. The journal also welcomes other breath-related topics.
Typical areas of interest include:
Big laboratory instrumentation: describing new state-of-the-art analytical instrumentation capable of performing high-resolution discovery and targeted breath research; exploiting complex technologies drawn from other areas of biochemistry and genetics for breath research.
Engineering solutions: developing new breath sampling technologies for condensate and aerosols, for chemical and optical sensors, for extraction and sample preparation methods, for automation and standardization, and for multiplex analyses to preserve the breath matrix and facilitating analytical throughput. Measure exhaled constituents (e.g. CO2, acetone, isoprene) as markers of human presence or mitigate such contaminants in enclosed environments.
Human and animal in vivo studies: decoding the ''breath exposome'', implementing exposure and intervention studies, performing cross-sectional and case-control research, assaying immune and inflammatory response, and testing mammalian host response to infections and exogenous exposures to develop information directly applicable to systems biology. Studying inhalation toxicology; inhaled breath as a source of internal dose; resultant blood, breath and urinary biomarkers linked to inhalation pathway.
Cellular and molecular level in vitro studies.
Clinical, pharmacological and forensic applications.
Mathematical, statistical and graphical data interpretation.